On the morning of June 19th, 2024, HemaCell Clinical R&D Center (hereafter "HemaCell") held a grand opening ceremony at Zhangjiang Gene Island. Several guests from the government, biomedical industry, and academia attended the ceremony to witness this significant moment. Zhang Weiwei, the deputy director of PKU-IICSH, was invited to attend the ceremony and participated in the round-table discussion.
At the ceremony, Dr. Zhu Fangfang, an alumna of the School of Life Sciences, Peking University and the founder and chairman of HemaCell, shared the company's development history and proposed prospects for the future of platelet regeneration. Hu Wei, the division director of Zhangjiang Science City Construction Management Office Economic Development Division, Xia Duo, the general manager of Shanghai International Medicine Zone, and Cai Li, Head of Pudong Women's Federation Women Development Department gave their speeches. Both Yuan Tao, secretary of the Party Working Committee and chairman of the Shanghai Zhangjiang Group and Tu Xiaozhong, the highest-level consultant of the Shanghai Federation of Returned Overseas Chinese expressed their great expectations of HemaCell's future development in Shanghai.
At the round-table meeting, Zhang Weiwei, the deputy director of PKU-IICSH, Dr. Zhu Fangfang, Prof. You Zhengwei, the dean of the Department of Composite Materials at The College of Materials Science and Engineering, Donghua University, and Li Bo from Weidu Investment (苇渡投资) discussed the issue of "New Quality Productivity - Exploring Productivity Innovation in the New Era" and covered multiple topics, including the concept of new quality productivity, and its effect and applications in different fields, aiming to provide innovative ideas and practical guidelines for various industries.
HemaCell is a stem cell-based biomedical company founded by experts from prestigious universities, including Stanford University, Harvard University, and Peking University. With the core technology of platelet regeneration, the company is dedicated to making breakthroughs in platelet regeneration and developing various applications of induced platelets. HemaCell has entered multiple markets, including transfusion, oncology, platelet disorders, sports medicine, cosmetic medicine, and anti-aging, through a unique perspective on market opportunities and problems. The company emphasizes a combination of over- and under-supplied products, focuses on technology, stresses cost reduction and efficiency improvement, and has achieved growth against the odds.
In June 2022, HemaCell received a Pre-Series A+ round investment made by Peking University's first Sci-tech Achievements Transformation Fund jointly initiated by Peking University, Beijing Science and Technology Innovation Fund, and other renowned investment institutions.
